Owlet, Inc.
NYSE:OWLTMedical - Devices
+$0.46 today
- Market cap
- $107.24M
- Beta
- 1.86
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$12.67
Volume 0.64M
Average 0.24M
OWLT Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Owlet, Inc.NYSE: OWLT
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $22.46M rose 6.4% year over year, behind the +26.8% change in trailing-twelve-month revenue. Sequentially, it fell 15.4% from the prior quarter. Over 3 fiscal years it compounded at +15.2% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $112.81M (+6.7%) for the fiscal year ending Dec 2026, a slowdown from the +35.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $22.46M-15.4% QoQ
- Last fiscal yearDec 2025
- $105.71M+35.4% YoY
- LTMMar 2026
- $107.06M+26.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.4% | +21.7% | +15.3 pp |
| 1 year | +35.4% | +6.7% | -28.7 pp |
| 3-year CAGR | +15.2% | +15.3% | +0.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 105.71M USD
- Year-over-year change
- +35.4%
- 4-year CAGR
- +8.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 105.71M | +35.4% |
| FY2024 | 2024-12-31 | 78.06M | +44.5% |
| FY2023 | 2023-12-31 | 54.01M | -22.0% |
| FY2022 | 2022-12-31 | 69.2M | -8.8% |
| FY2021 | 2021-12-31 | 75.84M | — |
Revenue vs competitors
How OWLT compares with its peers on the latest reported figures
- OWLT's LTM Mar 2026 revenue of $107.06M is the 2nd highest of the 10 companies compared; the peer median is $5.13M.
- Its year-over-year change of +26.8% is the highest of 8, against a peer median of +1.1%.
- Over three fiscal years its annual growth of +15.2% compares with a peer median of +15.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $116.26M | +23.2% | -0.3% | |
| LTM Mar 2026 | $107.06M | +26.8% | +15.2% | |
| LTM Mar 2026 | $57.7M | +1.1% | +18.2% | |
| LTM Mar 2026 | $34.38M | +16.0% | +25.2% | |
| LTM Mar 2026 | $32.29M | -14.3% | -9.3% | |
| LTM Mar 2026 | $5.13M | +23.0% | +132.0% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.85M | -25.7% | -15.8% |
| LTM Mar 2026 | $525K | -10.7% | +15.4% | |
| LTM Mar 2026 | $0 | — | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding OWLT) | $5.13M | +1.1% | +15.4% | |
Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.84M | 69.2M | 54.01M | 78.06M | 105.71M |
| Cost of Revenue | 40.78M | 45.89M | 31.42M | 38.75M | 52.18M |
| Gross Profit | 35.06M | 23.31M | 22.59M | 39.31M | 53.53M |
| Gross Margin | 46.2% | 33.7% | 41.8% | 50.4% | 50.6% |
| Research & Development | 21.43M | 27.9M | 10.35M | 9.8M | 14.08M |
| Selling, General & Admin | 69.42M | 80.04M | 40.87M | 49.73M | 47.72M |
| Operating Expenses | 90.85M | 107.93M | 51.22M | 59.53M | 61.79M |
| Depreciation & Amortization | 1.13M | 2.67M | 2.21M | 1.38M | 590K |
| EBITDA | (42.71M) | (75.53M) | (27.49M) | (9.47M) | (35.64M) |
| EBITDA Margin | -56.3% | -109.1% | -50.9% | -12.1% | -33.7% |
| Operating Income | (55.79M) | (84.62M) | (28.63M) | (20.22M) | (8.26M) |
| Operating Margin | -73.6% | -122.3% | -53.0% | -25.9% | -7.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 27.83M | 1.1M | 3.19M | 1.63M | 3.42M |
| Other Income / Expenses | (15.88M) | 5.31M | (4.26M) | 7.74M | (31.39M) |
| Income Before Tax | (71.67M) | (79.31M) | (32.89M) | (12.48M) | (39.65M) |
| Pre-Tax Margin | -94.5% | -114.6% | -60.9% | -16.0% | -37.5% |
| Income Tax Expense | 31K | 29K | 10K | 54K | 28K |
| Net Income | (71.7M) | (79.34M) | (32.9M) | (12.54M) | (39.68M) |
| Net Margin | -94.5% | -114.6% | -60.9% | -16.1% | -37.5% |
| EPS (Basic) | (12.47) | (9.97) | (4.53) | (0.83) | (2.24) |
| EPS (Diluted) | (12.47) | (9.97) | (4.53) | (0.83) | (2.24) |
| Weighted Avg Shares | 7.87M | 7.95M | 8.28M | 15.11M | 562.5M |
| Weighted Avg Shares (Diluted) | 7.87M | 7.95M | 8.28M | 15.11M | 562.5M |
Owlet, Inc.
NYSE:OWLT
Intrinsic Alpha fair value
Locked
Current Price
$3.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.